Interdisciplinary COPD intervention in primary care: a cluster randomised controlled trial
- PMID: 30792342
- DOI: 10.1183/13993003.01530-2018
Interdisciplinary COPD intervention in primary care: a cluster randomised controlled trial
Abstract
We evaluated the effectiveness of an interdisciplinary, primary care-based model of care for chronic obstructive pulmonary disease (COPD).A cluster randomised controlled trial was conducted in 43 general practices in Australia. Adults with a history of smoking and/or COPD, aged ≥40 years with two or more clinic visits in the previous year were enrolled following spirometric confirmation of COPD. The model of care comprised smoking cessation support, home medicines review (HMR) and home-based pulmonary rehabilitation (HomeBase). Main outcomes included changes in St George's Respiratory Questionnaire (SGRQ) score, COPD Assessment Test (CAT), dyspnoea, smoking abstinence and lung function at 6 and 12 months.We identified 272 participants with COPD (157 intervention, 115 usual care); 49 (31%) out of 157 completed both HMR and HomeBase. Intention-to-treat analysis showed no statistically significant difference in change in SGRQ at 6 months (adjusted between-group difference 2.45 favouring intervention, 95% CI -0.89-5.79). Per protocol analyses showed clinically and statistically significant improvements in SGRQ in those receiving the full intervention compared to usual care (difference 5.22, 95% CI 0.19-10.25). No statistically significant differences were observed in change in CAT, dyspnoea, smoking abstinence or lung function.No significant evidence was found for the effectiveness of this interdisciplinary model of care for COPD in primary care over usual care. Low uptake was a limitation.
Copyright ©ERS 2019.
Conflict of interest statement
Conflict of interest: M.J. Abramson reports grants from Boehringer Ingelheim, during the conduct of the study; grants from Pfizer, assistance with conference attendance and personal fees for consultancy from Sanofi, outside the submitted work. Conflict of interest: G. Russell has nothing to disclose. Conflict of interest: A.E. Holland is a current member of the Lung Foundation Australia COPD-X: Concise Guide for Primary Care Advisory Committee. Conflict of interest: N.A. Zwar is a current member of the Lung Foundation Australia COPD Guidelines Committee. Conflict of interest: B. Bonevski has nothing to disclose. Conflict of interest: A. Mahal has nothing to disclose. Conflict of interest: P. Eustace has nothing to disclose. Conflict of interest: E. Paul has nothing to disclose. Conflict of interest: K. Phillips is the Lung Foundation Australia General Manager of Consumer Programs. The Lung Foundation Australia works in collaboration and receives funding from pharmaceutical companies outlined in the foundation's annual reports (available at lungfoundation.com.au/about-us/annual-reports/). Conflict of interest: N.S. Cox has nothing to disclose. Conflict of interest: S. Wilson has nothing to disclose. Conflict of interest: J. George reports grants from Boehringer Ingelheim, during the conduct of the study; grants from Pfizer, and personal fees for consultancy from GSK, outside the submitted work; and is a current member of the Lung Foundation Australia COPD Guidelines Committee. Conflict of interest: J. Liang has nothing to disclose.
Comment in
-
Delivering high value therapies in COPD: the secret is in the marketing.Eur Respir J. 2019 Apr 25;53(4):1900215. doi: 10.1183/13993003.00215-2019. Print 2019 Apr. Eur Respir J. 2019. PMID: 31023865 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous